Du et al. (47) proposed that anti-CTLA-4 therapy and IRAEs have distinct mechanisms of action and showed that within the tumor microenvironment, CTLA-4 blockade locally decreases Tregs and allows other T-cells to elicit their effects. Here, CTLA4 is linked to neoplasm.